J. Cortés

发表

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

R. Gray, T. Powles, C. Wilson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

S Michiels, C Sotiriou, G Viale, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

L. Carey, A. Bardia, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

OP-ANNO180192 1634..1657

L. Norton, L. Carey, K. Gelmon, 2018 .

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

T. Sørlie, M. J. van de Vijver, C. Sotiriou, 2012 .

Acute lung injury associated with docetaxel and bevacizumab.

C. Serrano, J. Cortés, M. Montero, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

A. Iafrate, E. Felip, J. Tabernero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

P. Fasching, L. Pusztai, C. Denkert, 2021 .

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

P. Kristel, C. Caldas, O. Rueda, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

B. Kiely, L. Norton, K. Gelmon, 2020, Annals of Oncology.

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

A. Iafrate, E. Felip, P. Nuciforo, 2014 .

Efficacy of PI3K inhibitors in advanced breast cancer

F. André, T. Bachelot, M. Arnedos, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Research needs in breast cancer

C. Hudis, K. Gelmon, G. Sledge, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

N S El Saghir, L Biganzoli, N Harbeck, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

R. Schiff, C. Osborne, B. Adamo, 2019, Annals of Oncology.

Readthrough response of pathogenic premature termination codons at PTEN gene: implications in precision therapy for PHTS patients.

V. J. Cid, A. Erramuzpe, J. Cortés, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

F. André, S. Verma, C. Villarreal-Garza, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

C. Sotiriou, I. Bièche, D. Juric, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

C. Shapiro, P. Debruyne, S. Hurvitz, 2022, Annals of Oncology.

214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study

A. Bardia, F. Marmé, M. Motwani, 2022, Annals of Oncology.

168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study

A. Bardia, J. O’Shaughnessy, V. Diéras, 2022, Annals of Oncology.

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

C. Perou, L. Carey, A. Wolff, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.